BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21107572)

  • 1. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats.
    Sun JM; Nam MH; Chung JY; Im B; Lee SY; Suh YL; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):531-8. PubMed ID: 21107572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
    Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
    Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
    J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
    Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
    Sweeney CJ; Takimoto CH; Latz JE; Baker SD; Murry DJ; Krull JH; Fife K; Battiato L; Cleverly A; Chaudhary AK; Chaudhuri T; Sandler A; Mita AC; Rowinsky EK
    Clin Cancer Res; 2006 Jan; 12(2):536-42. PubMed ID: 16428497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
    Pestieau SR; Stuart OA; Sugarbaker PH
    Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of the novel antifolate pemetrexed to the brain.
    Dai H; Chen Y; Elmquist WF
    J Pharmacol Exp Ther; 2005 Oct; 315(1):222-9. PubMed ID: 15987831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.
    Hendricksen K; Moonen PM; van der Heijden AG; Molkenboer-Kuenen J; Hulsbergen-van de Kaa CA; Witjes JA
    Clin Cancer Res; 2006 Apr; 12(8):2597-601. PubMed ID: 16638871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
    Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
    Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
    Nakagawa K; Kudoh S; Matsui K; Negoro S; Yamamoto N; Latz JE; Adachi S; Fukuoka M
    Br J Cancer; 2006 Sep; 95(6):677-82. PubMed ID: 16940981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
    Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
    Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
    Latz JE; Rusthoven JJ; Karlsson MO; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):427-35. PubMed ID: 16322992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
    Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
    Llombart-Cussac A; Martin M; Harbeck N; Anghel RM; Eniu AE; Verrill MW; Neven P; De Grève J; Melemed AS; Clark R; Simms L; Kaiser CJ; Ma D
    Clin Cancer Res; 2007 Jun; 13(12):3652-9. PubMed ID: 17575230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
    Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.